Literature DB >> 26137918

Investigating incretin-based therapies as a novel treatment for depression in type 2 diabetes: Findings from the South London Diabetes (SOUL-D) Study.

C D Moulton1, J C Pickup2, S A Amiel2, K Winkley3, K Ismail3.   

Abstract

We aimed to investigate the association between incretin-based therapies and 1-year change in depressive symptoms in a cohort of 1735 patients with newly diagnosed type 2 diabetes. The incretin group experienced significant reduction in depressive symptoms compared to controls. This was independent of HbA1c and may be mediated by an anti-inflammatory mechanism. Crown
Copyright © 2015. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Depressive symptoms; Incretin-based therapies; Inflammation; Type 2 diabetes

Mesh：

Substances：

Year:  2015        PMID： 26137918     DOI： 10.1016/j.pcd.2015.06.003

Source DB:  PubMed          Journal:  Prim Care Diabetes        ISSN： 1878-0210            Impact factor:   2.459


  6 in total

Review 1.  The Bidirectional Relationship of Depression and Inflammation: Double Trouble.

Authors:  Eléonore Beurel; Marisa Toups; Charles B Nemeroff
Journal:  Neuron       Date:  2020-06-17       Impact factor: 17.173

2.  The Impact of Type 2 Diabetes in Parkinson's Disease.

Authors:  Dilan Athauda; James Evans; Anna Wernick; Gurvir Virdi; Minee L Choi; Michael Lawton; Nirosen Vijiaratnam; Christine Girges; Yoav Ben-Shlomo; Khalida Ismail; Huw Morris; Donald Grosset; Thomas Foltynie; Sonia Gandhi
Journal:  Mov Disord       Date:  2022-06-14       Impact factor: 9.698

3.  The Potential Role of the Dipeptidyl Peptidase-4-Like Activity From the Gut Microbiota on the Host Health.

Authors:  Marta Olivares; Valentina Schüppel; Ahmed M Hassan; Martin Beaumont; Audrey M Neyrinck; Laure B Bindels; Alfonso Benítez-Páez; Yolanda Sanz; Dirk Haller; Peter Holzer; Nathalie M Delzenne
Journal:  Front Microbiol       Date:  2018-08-22       Impact factor: 5.640

4.  Examining the risk of depression or self-harm associated with incretin-based therapies used to manage hyperglycaemia in patients with type 2 diabetes: a cohort study using the UK Clinical Practice Research Datalink.

Authors:  John-Michael Gamble; Eugene Chibrikov; William K Midodzi; Laurie K Twells; Sumit R Majumdar
Journal:  BMJ Open       Date:  2018-10-08       Impact factor: 2.692

Review 5.  GLP-1a: Going beyond Traditional Use.

Authors:  Lucas Fornari Laurindo; Sandra Maria Barbalho; Elen Landgraf Guiguer; Maricelma da Silva Soares de Souza; Gabriela Achete de Souza; Thiago Marques Fidalgo; Adriano Cressoni Araújo; Heron F de Souza Gonzaga; Daniel de Bortoli Teixeira; Thais de Oliveira Silva Ullmann; Katia Portero Sloan; Lance Alan Sloan
Journal:  Int J Mol Sci       Date:  2022-01-10       Impact factor: 5.923

Review 6.  Insights into a possible role of glucagon-like peptide-1 receptor agonists in the treatment of depression.

Authors:  Jan Detka; Katarzyna Głombik
Journal:  Pharmacol Rep       Date:  2021-05-18       Impact factor: 3.024
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.